

Published in final edited form as:

J Mol Biol. 2015 September 25; 427(19): 3031–3041. doi:10.1016/j.jmb.2015.07.016.

Updates to the integrated protein-protein interaction benchmarks: Docking benchmark version 5 and affinity benchmark version 2

Thom Vreven^{1,#}, Iain H. Moal^{2,†,#}, Anna Vangone^{3,#}, Brian G. Pierce^{1,&}, Panagiotis L. Kastritis^{3,\$}, Mieczyslaw Torchala⁴, Raphael Chaleil⁴, Brian Jiménez-García², Paul A. Bates^{4,*}, Juan Fernandez-Recio^{2,*}, Alexandre M.J.J. Bonvin^{3,*}, and Zhiping Weng^{1,*}

¹Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, U.S.A ²Joint BSC-CRG-IRB Research Program in Computational Biology, Life Sciences Department, Barcelona Supercomputing Center, C/Jordi Girona 29, 08034 Barcelona, Spain ³Bijvoet Center for Biomolecular Research, Faculty of Science, Utrecht University, 3584CH Utrecht, The Netherlands ⁴Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln's Inn Fields Laboratories, London WC2A 3LY, United Kingdom

Abstract

We present an updated and integrated version of our widely used protein-protein docking and binding affinity benchmarks. The benchmarks consist of non-redundant, high quality structures of protein-protein complexes along with the unbound structures of their components. Fifty-five new complexes were added to the docking benchmark, 35 of which have experimentally-measured binding affinities. These updated docking and affinity benchmarks now contain 230 and 179 entries, respectively. In particular, the number of antibody-antigen complexes has increased significantly, by 67% and 74% in the docking and affinity benchmarks, respectively.

We tested previously developed docking and affinity prediction algorithms on the new cases. Considering only the top ten docking predictions per benchmark case, a prediction accuracy of 38% is achieved on all 55 cases, and up to 50% for the 32 rigid-body cases only. Predicted affinity scores are found to correlate with experimental binding energies up to r=0.52 overall, and r=0.72 for the rigid complexes.

#These authors contributed equally to this work

Supplementary material

CDR definition used for docking antibody-antigen complexes with HADDOCK, predicted affinities listed by benchmark entry, experimental conditions of the affinities measurements, and the full references to the experimentally measured affinities. The docking benchmark is hosted at http://zlab.umassmed.edu/benchmark, and the affinity benchmark at http://bmm.cancerresearchuk.org/~bmmadmin/Affinity

^{*}Correspondence to Paul A. Bates (paul.bates@crick.ac.uk), Juan Fernandez-Recio (juan.fernandez@bsc.es), Alexandre M.J.J. Bonvin (a.m.j.j.bonvin@uu.nl), and Zhiping Weng (zhiping.weng@umassmed.edu).

Expresent address: Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, U.S.A.

^{\$}present address: European Molecular Biology Laboratory, Meyerhofstraβe 1, 69117 Heidelberg, Germany present address: EMBL-European Bioinformatics Institute, Hinxton, Cambridge, CB10 1SD, United Kingdom

Keywords

Protein-protein complex structure; Antibody-antigen; Conformational change; Protein-protein interface; Binding free energy

Introduction

Protein-protein interactions are among the most important processes in biology, playing fundamental roles in the immune system, signaling pathways, and enzyme inhibition. Proteome-wide studies have revealed that most proteins interact with other proteins [1]. The experimental characterization of the structure of a protein-protein complex is, however, difficult and not always successful. To complement experimental approaches, computational techniques for the prediction of protein complexes have been developed over the years, stimulated by the CAPRI experiment (Critical Assessment of PRedicted Interactions) [2]. Computational approaches for modeling protein-protein complex structures include ab-initio docking methods [3,4], homology-based methods based on the experimental structures of similar complexes [5–11], and integrative, information-driven methods [12], These approaches typically attempt to predict the most likely structure of a complex, but are not designed to predict how strongly the proteins bind or whether they bind at all. Thus a more complete computational description of protein-protein interaction also requires algorithms that can predict binding affinities. Although energy functions for affinity prediction and the ranking of docking poses are related, they are often developed specifically for their respective purposes and so far have shown varying and rather limited performance [13]. Example areas where scoring functions can be improved are entropic contributions [14], solvent effects [15], and the optimal combination of terms [16].

Essential for the development of computational algorithms are training and test sets that are reliable and sufficiently large. It is computationally daunting to sift the Protein Data Bank for structures of protein-protein complexes; the experimental conditions and accuracies of these structures vary widely and are not always straightforward to assess, and neither is the definition of the biological unit. Recognizing this, various benchmarks were developed that attempt to collect a reliable and well-understood set of data. Our docking benchmark, which after its initial development [17] has seen three updates [18–20], is widely used for developing and assessing docking methods. Key features are the availability of both the complex structure and the unbound structures of the component proteins, non-redundancy, and reliability of the data. Other benchmarks include DOCKGROUND [21], which also focuses on protein-protein interactions, and benchmarks that contain complexes of proteins with nucleic acids [22,23].

More recently we used our protein-protein docking benchmark as a starting point for developing a structure-based affinity benchmark [24,25], which includes the entries from our docking benchmark for which experimental binding affinities were available. The affinity benchmark has been used for the development of algorithms for predicting protein-protein binding free energies, with a typical correlation coefficient of r=0.6 with experimentally measured binding free energies [26–28].

In this paper we present updates to our docking and affinity benchmarks, of which the development is tightly integrated. We added 55 new protein-protein complexes to the docking benchmark, for 35 of which experimental affinities could be found that were added to the affinity benchmark. These new additions to both benchmarks were then used, as an independent test set, to assess the performance of four docking algorithms and a large panel of affinity prediction algorithms that had been previously developed without seeing any of the new cases. This allowed us to assess the performance of docking and affinity predictions, both of which remained limited due to conformational changes, with an indication that low affinity complexes were also more challenging to dock.

Results and Discussion

Composition

We added 55 cases to the docking benchmark (Table 1). PDB entries 3AAD and 3P57 show two and three distinct binding modes, respectively. As in the previous versions of the benchmark, the complexes that display multiple binding modes were split into different cases. This represents an increase of 31% over the previous 175 cases. We could find binding affinity data for 35 of the cases, which brought the total number of cases in the affinity benchmark to 179, a 24% increase. In Table 2 we show the composition of the updated benchmarks compared with the previous versions. The most noticeable increase is for antibody-antigen complexes: from 24 cases to 40 cases in the docking benchmark and from 19 cases to 33 cases in the affinity benchmark, which reflects a surging interest in antibody-based therapeutics.

In the previous versions of the benchmarks, some categories are underrepresented, most notably the antibody-antigen cases (14%) and difficult cases (15%), while rigid-body cases are overrepresented (68%). Although there still is overrepresentation and underrepresentation in the updated benchmark, the newly added cases do not worsen the representation of any category, and achieve a more balanced composition for most categories. We examined the new cases on various properties related to size and flexibility of the component proteins, but only found the total solvent accessible surface area of the component proteins to be significantly smaller in docking benchmark 4 than the 55 new cases (p-value=0.05; Kolmogorov-Smirnov test), with average total surface areas of ~24,000 Å² and ~29,000 Å², respectively. It is not clear, however, to what extent this difference reflects changes in the content of the PDB. Finally, the cases in the docking benchmark that involve NMR structures increased from 16 cases (9%) in version 4 to 32 cases (14%) in version 5.

Performance of docking algorithms

Four docking algorithms (see Material and Methods) we applied to the new cases and their results are shown in Figure 1A. SwarmDock [29,30], PyDock [31], and ZDOCK [32,33] are *ab-initio* methods, whereas HADDOCK uses bioinformatics predictions to drive the docking [34], in this particular case it uses CPORT to predict interface residues [35] and PARATOME [36] to identify CDR loops of antibodies (see Methods). Overall the success rates (at least one acceptable prediction for a benchmark case) ranged between 5–16% for

the top prediction, 20–38% for the top 10 predictions, and 40–67% for the top 100 predictions, comparable to the success rates on version 4 of the docking benchmark using SwarmDock and ZDOCK [37,38]. As expected, the success rate was much higher for the rigid-body category, with the success rates for the top 10 predictions at 31–50%, compared to 4–22% for the medium and difficult cases. The success rates also varied according to biological category, highest for enzyme containing complexes (29–41%) followed by the antibody/antigen complexes (13–38%) and finally the other complexes (5–36%).

We observed that the performances of the different docking algorithms were correlated; for 25% of the rigid-body cases, not a single acceptable solution was found in the top 10 predictions by any of the algorithms, and for 22% cases all four methods succeeded. These figures are much higher than would be expected if the complexes with correct predictions were randomly distributed amongst the rigid-body cases (16% and 2%, respectively). Some insight into why some interactions were inherently easier to dock than others, even within the rigid-body category, can be gleaned by focusing on the cases for which affinities are available. When all the docking algorithms failed to find an acceptable solution in the top 10 predictions, the affinity predictors also predicted weak binding energies (3EOA, 3BIW, 4M76, 3RVW, 4GXU, 3H2V). This is either because the complexes are indeed of low affinity, or due to deficiencies in the energy functions used in both docking and affinity prediction. The success rates were higher for enzyme containing and antibody-antigen complexes than for other complexes, as the latter tend to form weaker interactions.

We searched for features indicative of a successful docking outcome. We define a successful run as a benchmark case for which at least three out of four docking algorithms yielded an acceptable or better prediction in the top 100 predictions, while an unsuccessful docking run had at most one algorithm with an acceptable prediction in the top 100 predictions. We asked which features could separate the cases with successful docking runs from the cases with unsuccessful docking runs. Because a major driving force in many protein-protein docking algorithms is the desolvation of the protein components [28], we computed the buried interface area (ASA) upon complex formation, which is a good measure for desolvation. We further hypothesized that strong binders were easier to dock than weak binders. Indeed ASA and experimentally measured binding free energy achieved a good separation of the two sets of cases with successful and unsuccessful docking runs (Figure 2). Note that the correlation between ASA and the experimental binding energy is low, as reported in Figure 1B and discussed below. These two features were individually mildly predictive of docking success (for example, the seven strongest binders all resulted in successful docking runs), the combination of them could almost cleanly separate the successful and unsuccessful docking runs. Below the separating line, 79% docking runs were successful, and above the line the docking performance drops to 31%. The outlier 2GAF [39] has the largest interface area of all the cases and a binding energy stronger than any of the other cases with unsuccessful docking runs. Below we discuss this complex in more detail.

Performance of affinity prediction algorithms

The change in buried surface area, ASA, does not correlate well with binding energy (r= -0.16), even for the rigid complexes (I-RMSD < 1.0Å, r=-0.28), due to complexes with large ASA but low affinity, such as the snpA protease/inhibitor complex (4HX3), as well as high affinity complexes with low surface area such as the C836 (3L5W) and carlumab (4DN4) antibodies, which are highly optimized for cytokine binding. Similarly, the binding energy does not correlate highly with I-R-SD (r=-0.24), and only a small improvement is found using a minimal linear model combining ASA and I-RMSD (r=0.31) [40]. We further evaluated a number of prediction methods that include the specific geometry and composition of the interaction (Figure 1B). This yielded overall correlations of up to r=0.53, with a predictive power much higher for rigid complexes, up to r=0.75, than for the flexible cases, up to r=0.53. The best performing methods were trained using either the first version of the affinity benchmark [25] or using changes in affinity upon mutation [41], yet these functions yielded lower correlations on the new benchmark cases than the best correlations were lower for the statistical potentials and docking scores.

For some of the complexes, the predictions were consistently poor across all methods. All methods underestimated the affinities for the antibody/hemagglutinin complex (4GXU), which features a glycosylated asparagine at the periphery of the interface, the C3D/integrin α -M complex (4M76), for which the interaction is mediated via a Ca²⁺ ion at the core of the interface, and the efalizumab/integrin α -L complex (3EOA), which is the most rigid interaction in the benchmark (I-RMSD = 0.39 Å). On the other hand, all methods overestimated the affinities for the actin/twinfilin (3DAW), ALM57/integrin α -L (3HI6), TolA/G3P (2X9A) and HIF2/ARNT (3F1P) complexes, all of which have high flexibility, for which the energy penalty of conformational rearrangement may not be well estimated.

Highlighted case: Poly(A) polymerase VP55/Vaccinia protein VP39 (2GAF)

Figure 2 shows that the combination of experimentally measured binding energy and buried surface area forms a good indicator for a successful docking run. The complex of Poly (A) polymerase VP55 and Vaccinia protein VP39 (2GAF) [39], however, is a striking outlier. Only a single docking protocol was successful, despite 2GAF having the largest buried surface area of all complexes and stronger binding than any of the other complexes that had at most one successful docking run. Furthermore, this complex belongs to the rigid-body category, with an I-RMSD of 0.69 Å, and we did not find co-factors or other aspects that might complicate the docking. We studied 2GAF in more detail to understand the poor docking performance. Inspection of the structure (Figure 3) suggests that the difficulty may be related to the deep cavity of the receptor being completely filled by the ligand. To quantify this, we calculated the degree of encapsulation of a protein by its binding partner using C_{α} atoms, and performed the same calculation for all the benchmark cases in Figure 2. We found that 39 residues of the vaccinia protein VP39 are within the cavity of the Poly(A) polymerase VP55 (indicated in blue in Figure 3). This is the highest number observed in the set of proteins considered for Figure 2; 4FOI and 3BX7 have 25 and 12 residues encapsulated, respectively, while all other proteins have fewer than ten residues within the cavities (39 proteins show zero resides). Presumably the tight fit seen in 2GAF renders the

mouth of the energy funnel narrow, which may impact the ability of docking algorithms to find and enter the energy funnel. In addition, the tight fit may cause difficulty for grid-based methods (ZDOCK, PyDock), because even small deviations from the ideal position, resulting from the discreet rigid-body conformational parameters, may cause clashes that prevent favorable scores. Indeed, for a run with a finer rotational sampling (6° vs. the default of 15°), ZDOCK found a high-accuracy prediction at rank 23. SwarmDock was able to find a solution in the top 5. Small conformational changes allowed by SwarmDock, which may have alleviated steric clashes at the funnel entrance, could have facilitated a smoother entry to the binding funnel. Indeed, the lowest frequency normal mode corresponds to the opening of the binding cavity, allowing ligand insertion. In the case of HADDOCK, it was the low quality of the bioinformatics predictions for the ligand binding site (recall of 7%) that prevented the sampling of near-native solutions. Docking with center-of-mass or random ambiguous interaction restraints (two ab-initio docking modes of HADDOCK) does generate acceptable solutions in the top 50 (data not shown). In general, it appears that the poor performance of the docking algorithms for 2GAF is caused by the inability to correctly sample or find the native orientation of the ligand within the receptor cavity. This makes 2GAF an exception to the general consensus in the field that failures of docking protocols are caused either by inaccuracies of the scoring functions (including explicit solvation and entropy effects) or the difficulty of modeling protein conformational changes [43,44].

Conclusions

We have presented updated versions to our widely used protein-protein docking and affinity benchmarks with respectively 55 and 35 new entries. This represents relative increases of 31% and 24% cases, respectively compared with the previous versions. The updated benchmarks have slightly improved the balance with respect to both complex types and the range of conformational changes between bound and unbound forms. They are available from the following sites: http://zlab.umassmed.edu/benchmark (docking benchmark) and http://bmm.cancerresearchuk.org/~bmmadmin/Affinity (affinity benchmark).

We analyzed the performance of four different docking methods and a comprehensive set of state-of-the-art protein-protein complex affinity prediction methods. We found that the newly added complexes provide a challenging test set for both docking and affinity prediction algorithms: Structure predictions success rates and correlations with experimentally obtained affinities are lower than reported using previous versions of the benchmark. These updated benchmarks will aid the community in improving these algorithms and increasing our understanding of biomolecular interactions.

Methods

Benchmark construction

We collected new structures for our benchmarks from the Protein Data Bank (PDB) [45] using a semiautomatic pipeline. We first used the BLAST sequence homology search tool [46] to find protein-protein complexes for which the experimental structures of both the complex and the unbound component proteins were available. We also used the SACS resource [47] to collect a candidate list of antibody-antigen complexes. These complexes

were then filtered using various quality criteria: (1) the complex structure needed to be determined by X-ray crystallography, the unbound structures by either X-ray crystallography or nuclear magnetic resonance (NMR); (2) the sequence identity between bound and unbound chains needed to be at least 96% with an alignment coverage larger than 80%; (3) the X-ray resolution needed to be 3.25 Å or better; (4) chains needed to consist of at least 30 residues.

While constructing the previous versions of our docking benchmark [17–20], we deemed two complexes redundant when the pairs of interacting domains were the same at the SCOP [48] family level. Antibody-antigen complexes were considered redundant only when the SCOP families of the antigens were identical, and at least 80% of the antigen interface residues were shared between the two complexes. We used SCOPe 2.03 [49] (previously named SCOP 1.75C), which represented a limited update with respect to the 1.75 release used for the first four versions of the docking benchmark. To further compensate for the lack of SCOP coverage for the most recently solved PDB structures, we inferred their SCOP family level assignments using the older PDB entries with identical sequences and known SCOP IDs.

We manually investigated the candidate complexes extensively, consulting the literature associated with the PDB entries. We checked whether any residues were missing or mutated in the interface (allowing such residues only if binding would not be affected), and whether co-factors that affect binding were present or compatible in both bound and unbound forms. The starting point for the manual step was the first biological assembly listed in the PDB, although in a number of cases these were not accurate and an alternative assembly had to be used. When multiple entries were available for a complex or a component protein, we chose the entry that had the best overall structure quality. This was to some extent a subjective criterion, as we had to balance all the aforementioned features in the decision. For component proteins with NMR structures we chose the model that had the lowest interface root mean square deviation (I-RMSD) from the bound structure. Finally, we prepared structure files that included the fewest protein chains that correctly reflected the binding process, aligned the bound and unbound structures, and retained only those HETATM fields that we deemed biologically relevant.

We evaluated several properties from the structure files. The change in solvent accessible surface area (ASA) upon complex formation was calculated using the NACCESS algorithm [50]. The I-RMSD was calculated by superposing the unbound component proteins onto their bound forms, using the C_α atoms for residues that had any atom within 10 Å of any atom of the binding partner. We also assessed the expected difficulty of a benchmark entry for protein-protein docking algorithms [17–20]. Complexes with I-RMSD > 2.2 Å were considered difficult, and complexes with I-RMSD < 1.5 Å were considered rigid-body if their $f_{non-nat}$ [51] were < 0.40. All other complexes were considered to be of medium docking difficulty.

We then used the set of complexes as a starting point for extending the structural affinity benchmark. For many entries, affinities were reported multiple times either by different groups or using different techniques. These measurements were mostly in mutual

accordance with one another, typically within one order of magnitude in terms of equilibrium constant. When selecting the value to include in the benchmark, priority was given to affinities reported for samples matching the sequences of the reported structures of the complexes. When this criterion could not be met or still resulted in multiple values preference was based on sequence similarity and the measurement method. As in the first version of the affinity benchmark, most affinities were measured using surface plasmon resonance, isothermal titration calorimetry, or spectroscopic methods. The affinities of four new cases were measured using the more recent thermophoresis and bio-layer interferometry technologies. We also collected experimental conditions and additional thermodynamic and kinetic data whenever available. Affinities were measured at a pH in the 7–8 range, typically within the 20–25°C temperature range, and with an ionic strength of around 150 mM. In the context of affinity prediction we consider complexes with I-RMSD < 1.0 Å as rigid-body and the remaining complexes flexible.

Docking algorithms

ZDOCK is an FFT-based rigid-body docking algorithm that performs a grid-based exhaustive search with a 15° or 6° rotational sampling in three-dimensional (3D) rotational space and a 1.2 Å sampling in the 3D translational space [32,33,38,52]. For each combination of the three rotational angles, the best scoring prediction in the translational space is retained, yielding 3600 or 54000 predictions for the 15° and the 6° sampling respectively. Here we report results obtained using the 15° sampling. We used ZDOCK version 3.0.2 that uses the IFACE [53] scoring function and the advanced 3D convolution library [54].

SwarmDock is a flexible docking method employing a population-based memetic algorithm that combines a modified particle swarm optimization global search with an adaptive random local search [29,30]. Elastic network normal mode analysis is used to model flexibility, and the algorithm simultaneously optimizes translational, quaternion and normal coordinates, using the DComplex statistical potential as objective function [55]. The algorithm was run at the SwarmDock server [37]; swarms are initialized around ca. 120 points surrounding the receptor and the algorithm was run four times from each starting point for 600 iterations. The lowest energy solutions found in each run were ranked using the centroid potential of Tobi [56] and clustered, retaining only the lowest energy member of each cluster.

PyDock [31] is a protein-protein docking protocol built upon FTDock [57], an FFT based method that searches for geometrically complementary rigid-body poses in the translational and rotational space. FTDock predicts 10,000 poses which are then scored using an empirical potential composed of electrostatic interaction (Coulombic energy with a distance-dependent dielectric constant $\varepsilon = 4.0r$ and charges specified by the AMBER94 force field [58], truncated to be in between 1.0 and -1.0 kcal/mol), desolvation (based on atomic solvation parameters optimized for rigid-body docking), and a limited (10%) contribution from the van der Waals energy (6–12 Lennard-Jones potential with atomic parameters from the AMBER94 force field, truncated to be below 1.0 kcal/mol).

HADDOCK (High Ambiguity Driven DOCKing) [34] is a semi-flexible docking protocol that uses bioinformatics predictions and biochemical/biophysical interaction data to drive the docking process. It uses CNS (Crystallography and NMR system) [59] as its structure calculation engine. The protocol consists of three steps: i) randomization of orientation and rigid-body docking via energy minimization driven by interaction restraints (it0), ii) semi-flexible refinement in the torsional angle space in which side-chain and backbone atoms of the interface residues are allowed to move (it1) and iii) Cartesian dynamics refinement in explicit solvent, typically water. The final structures are clustered using the pairwise backbone ligand interface RMSD and the resulting clusters ranked according to the HADDOCK score (weighted sum of the restraint energy, the van der Waals and electrostatic energies based on OPLS parameters [60] and a desolvation energy term [61]). Note that in the docking performance analysis presented here, no clustering was performed and individual models were selected based on their HADDOCK score.

We used the HADDOCK web server [62], outputting 10000/400/400 models for the three stages of the protocol. Restraints to drive the docking were derived from bioinformatics predictions by CPORT [35], except for the antibody-antigen complexes for which complementarity-determining regions (CDRs) identified with PARATOME [36] were defined as active, and all solvent-accessible residues of the antigen were used as passive residues to define ambiguous interaction restraints to drive the docking. The predicted interfaces (and their recall and precision) used for docking are available at the SBGRid Data Bank, along with all docking decoys and HADDOCK input files from the deposited HADDOCK docking set [63].

Affinity prediction algorithms

ZAPP predicts protein-protein binding free energies using a linear combination of nine energy terms and a constant [26]. Only one term uses the unbound structures in addition to the complex structures, while the other eight terms only require the complex structure.

ConsBind is an affinity prediction method based on machine learning in which the predicted affinity is a consensus of four learners [42]: multivariate adaptive regression splines (MARS), random forest regression (RF), radial basis function (RBF) interpolation, and an M5′ regression tree (M5′). The learners were trained using 143 of the 144 affinities in the previous affinity benchmark [25] with all 108 features extracted from the bound structures using the CCharPPI web server [64]. Information from the unbound structures was not used. The final consensus score is the arithmetic mean of the four learners.

Solvebind is a binding affinity prediction method based on the global surface model of Kastritis et al. [27], combining the number of atoms in the interface ($N_{AtomsINT}$) and the percentages of charged and polar residues in the non-interacting surface ($N_{AtomsINT}$) and $N_{AtomsINT}$ and $N_{AtomsINT}$):

$$-logK_d = \alpha \cdot \%AA_{pol}^{NIS} + \beta \cdot \%AA_{char}^{NIS} + \gamma \cdot N_{AtomsINT} + \delta$$

with $\alpha = 0.0857$, $\beta = -0.0685$, $\gamma = 0.0262$, and $\delta = 3.0125$ (obtained after four-fold cross-validation based on the rigid-body complexes of the previous affinity benchmark [25]). Properties of the non-interacting surface were found to correlate with affinity [13,27] and may regulate solvation and electrostatic contributions to binding affinity [27,65].

Besides the aforementioned binding affinity prediction methods developed in our groups, we also assessed the minimal affinity model of Janin (ASA/RMSD) [40], buried surface area (ASA), the DOPE [66] and DComplex [55] statistical potentials, the PyDock [31], SIPPER [67], ZDOCK [68] and FireDock [69] docking scores, as well as contact potentials (G_AW, G_AU, G_CW, G_CU) [41] and a surface energy model (G_V) [70] derived from mutation data.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- Wodak SJ, Vlasblom J, Turinsky AL, Pu S. Protein-protein interaction networks: the puzzling riches. Curr Opin Struc Biol. 2013; 23:941–53.
- 2. Janin J, Henrick K, Moult J, Eyck LT, Sternberg MJE, Vajda S, et al. CAPRI: a Critical Assessment of PRedicted Interactions. Proteins. 2003; 52:2–9. [PubMed: 12784359]
- 3. Ritchie DW. Recent progress and future directions in protein-protein docking. Curr Protein Pept Sci. 2008; 9:1–15. [PubMed: 18336319]
- Smith GR, Sternberg MJE. Prediction of protein-protein interactions by docking methods. Curr Opin Struc Biol. 2002; 12:28–35.
- 5. Lu L, Lu H, Skolnick J. MULTIPROSPECTOR: An algorithm for the prediction of protein-protein interactions by multimeric threading. Proteins. 2002; 49:350–64. [PubMed: 12360525]
- 6. Mukherjee S, Zhang Y. Protein-protein complex structure predictions by multimeric threading and template recombination. Structure. 2011; 19:955–66. [PubMed: 21742262]
- 7. Szilagyi A, Zhang Y. Template-based structure modeling of protein–protein interactions. Curr Opin Struc Biol. 2014; 24:10–23.
- 8. Ogmen U, Keskin O, Aytuna AS, Nussinov R, Gursoy A. PRISM: protein interactions by structural matching. Nucleic Acids Research. 2005; 33:W331–226. [PubMed: 15991339]
- Tuncbag N, Gursoy A, Nussinov R, Keskin O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat Protoc. 2011; 6:1341–54. [PubMed: 21886100]
- 10. Sinha R, Kundrotas PJ, Vakser IA. Docking by structural similarity at protein-protein interfaces. Proteins. 2010; 78:3235–41. [PubMed: 20715056]
- 11. Vreven T, Hwang H, Pierce BG, Weng Z. Evaluating template-based and template-free protein-protein complex structure prediction. Brief Bioinformatics. 2014; 15:169–76. [PubMed: 23818491]
- 12. Rodrigues JPGLM, Bonvin AMJJ. Integrative computational modeling of protein interactions. Febs J. 2014; 281:1988–2003. [PubMed: 24588898]
- 13. Kastritis PL, Bonvin AMJJ. Molecular origins of binding affinity: seeking the Archimedean point. Curr Opin Struc Biol. 2013; 23:868–77.
- 14. Kastritis PL, Bonvin AMJJ. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J R Soc Interface. 2013; 10:20120835. [PubMed: 23235262]
- 15. Kastritis PL, Visscher KM, van Dijk ADJ, Bonvin AMJJ. Solvated protein-protein docking using Kyte-Doolittle-based water preferences. Proteins. 2013; 81:510–8. [PubMed: 23161727]

 Moal IH, Torchala M, Bates PA, Fernandez-Recio J. The scoring of poses in protein-protein docking: current capabilities and future directions. Bmc Bioinformatics. 2013; 14:286. [PubMed: 24079540]

- 17. Chen R, Mintseris J, Janin J, Weng Z. A protein-protein docking benchmark. Proteins. 2003; 52:88–91. [PubMed: 12784372]
- 18. Mintseris J, Wiehe K, Pierce B, Anderson R, Chen R, Janin J, et al. Protein-Protein Docking Benchmark 2. 0: an update. Proteins. 2005; 60:214–6. [PubMed: 15981264]
- 19. Hwang H, Pierce B, Mintseris J, Janin J, Weng Z. Protein-protein docking benchmark version 3. 0. Proteins. 2008; 73:705–9. [PubMed: 18491384]
- 20. Hwang H, Vreven T, Janin J, Weng Z. Protein-protein docking benchmark version 4. 0. Proteins. 2010; 78:3111–4. [PubMed: 20806234]
- Douguet D, Chen H-C, Tovchigrechko A, Vakser IA. DOCKGROUND resource for studying protein-protein interfaces. Bioinformatics. 2006; 22:2612–8. [PubMed: 16928732]
- 22. van Dijk M, Bonvin A. A protein–DNA docking benchmark. Nucleic Acids Research. 2008; 36:e88. [PubMed: 18583363]
- Perez-Cano L, Jiménez-García B, Fernandez-Recio J. A protein-RNA docking benchmark (II): extended set from experimental and homology modeling data. Proteins. 2012; 80:1872–82. [PubMed: 22488990]
- Kastritis PL, Bonvin AMJJ. Are Scoring Functions in Protein-Protein Docking Ready To Predict Interactomes? Clues from a Novel Binding Affinity Benchmark. J Proteome Res. 2010; 9:2216– 25. [PubMed: 20329755]
- 25. Kastritis PL, Moal IH, Hwang H, Weng Z, Bates PA, Bonvin AMJJ, et al. A structure-based benchmark for protein-protein binding affinity. Protein Sci. 2011; 20:482–91. [PubMed: 21213247]
- 26. Vreven T, Hwang H, Pierce BG, Weng Z. Prediction of protein-protein binding free energies. Protein Sci. 2012; 21:396–404. [PubMed: 22238219]
- Kastritis PL, Rodrigues JPGLM, Folkers GE, Boelens R, Bonvin AMJJ. Proteins feel more than they see: fine-tuning of binding affinity by properties of the non-interacting surface. J Mol Biol. 2014; 426:2632–52. [PubMed: 24768922]
- 28. Moal IH, Moretti R, Baker D, Fernandez-Recio J. Scoring functions for protein-protein interactions. Curr Opin Struc Biol. 2013; 23:862–7.
- 29. Moal IH, Bates PA. SwarmDock and the use of normal modes in protein-protein docking. Int J Mol Sci. 2010; 11:3623–48. [PubMed: 21152290]
- Li X, Moal IH, Bates PA. Detection and refinement of encounter complexes for protein-protein docking: taking account of macromolecular crowding. Proteins. 2010; 78:3189–96. [PubMed: 20552581]
- 31. Cheng TM-K, Blundell TL, Fernandez-Recio J. pyDock: electrostatics and desolvation for effective scoring of rigid-body protein-protein docking. Proteins. 2007; 68:503–15. [PubMed: 17444519]
- 32. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003; 52:80–7. [PubMed: 12784371]
- 33. Chen R, Weng Z. A novel shape complementarity scoring function for protein-protein docking. Proteins. 2003; 51:397–408. [PubMed: 12696051]
- Dominguez C, Boelens R, Bonvin A. HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. Journal of the American Chemical Society. 2003; 125:1731–7. [PubMed: 12580598]
- 35. De Vries SJ, Bonvin AMJJ. CPORT: a consensus interface predictor and its performance in prediction-driven docking with HADDOCK. PLoS ONE. 2011; 6:e17695. [PubMed: 21464987]
- 36. Kunik V, Ashkenazi S, Ofran Y. Paratome: an online tool for systematic identification of antigenbinding regions in antibodies based on sequence or structure. Nucleic Acids Research. 2012; 40:W521–4. [PubMed: 22675071]
- 37. Torchala M, Moal IH, Chaleil RAG, Fernandez-Recio J, Bates PA. SwarmDock: a server for flexible protein-protein docking. Bioinformatics. 2013; 29:807–9. [PubMed: 23343604]

38. Pierce BG, Wiehe K, Hwang H, Kim BH, Vreven T, Weng Z. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics. 2014; 30:1771–3. [PubMed: 24532726]

- 39. Moure CM, Bowman BR, Gershon PD, Quiocho FA. Crystal structures of the vaccinia virus polyadenylate polymerase heterodimer: insights into ATP selectivity and processivity. Mol Cell. 2006; 22:339–49. [PubMed: 16678106]
- 40. Janin J. A minimal model of protein-protein binding affinities. Protein Sci. 2014; 23:1813–7. [PubMed: 25270898]
- 41. Moal IH, Fernandez-Recio J. Intermolecular contact potentials for protein–protein interactions extracted from binding free energy changes upon mutation. J Chem Theory Computation. 2013; 9:3715–727
- 42. Moal IH, Agius R, Bates PA. Protein-protein binding affinity prediction on a diverse set of structures. Bioinformatics. 2011; 27:3002–9. [PubMed: 21903632]
- 43. Bonvin A. Flexible protein-protein docking. Curr Opin Struc Biol. 2006; 16:194-200.
- 44. Zacharias M. Accounting for conformational changes during protein-protein docking. Curr Opin Struc Biol. 2010; 20:180–6.
- 45. Berman HM. The Protein Data Bank. Nucleic Acids Research. 2000; 28:235–42. [PubMed: 10592235]
- 46. Altschul S. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research. 1997; 25:3389–402. [PubMed: 9254694]
- 47. Allcorn LC, Martin ACR. SACS--Self-maintaining database of antibody crystal structure information. Bioinformatics. 2002; 18:175–81. [PubMed: 11836226]
- 48. Murzin AG, Brenner SE, Hubbard T, Chothia C. SCOP: A structural classification of proteins database for the investigation of sequences and structures. J Mol Biol. 1995; 247:536–40. [PubMed: 7723011]
- 49. Fox NK, Brenner SE, Chandonia J-M. SCOPe: Structural Classification of Proteins—extended, integrating SCOP and ASTRAL data and classification of new structures. Nucleic Acids Research. 2014; 42:D304–9. [PubMed: 24304899]
- 50. Hubbard, SJ.; Thornton, JM. "NACCESS," Computer Program. Department of Biochemistry and Molecular Biology, University College London; 1993.
- 51. Méndez R, Leplae R, De Maria L, Wodak SJ. Assessment of blind predictions of protein-protein interactions: current status of docking methods. Proteins. 2003; 52:51–67. [PubMed: 12784368]
- 52. Vreven T, Pierce BG, Hwang H, Weng Z. Performance of ZDOCK in CAPRI rounds 20–26. Proteins. 2013; 81:2175–82. [PubMed: 24123140]
- 53. Mintseris J, Pierce B, Wiehe K, Anderson R, Chen R, Weng Z. Integrating statistical pair potentials into protein complex prediction. Proteins. 2007; 69:511–20. [PubMed: 17623839]
- 54. Pierce BG, Hourai Y, Weng Z. Accelerating protein docking in ZDOCK using an advanced 3D convolution library. PLoS ONE. 2011; 6:e24657. [PubMed: 21949741]
- 55. Liu S, Zhang C, Zhou H, Zhou Y. A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Proteins. 2004; 56:93–101. [PubMed: 15162489]
- Tobi D. Designing coarse grained-and atom based-potentials for protein-protein docking. Bmc Struct Biol. 2010; 10:40. [PubMed: 21078143]
- 57. Gabb HA, Jackson RM, Sternberg MJ. Modelling protein docking using shape complementarity, electrostatics and biochemical information. J Mol Biol. 1997; 272:106–20. [PubMed: 9299341]
- 58. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. Journal of the American Chemical Society. 1995; 117:5179–97.
- Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998; 54:905–21. [PubMed: 9757107]
- 60. Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. Journal of the American Chemical Society. 1988; 110:1657–66.

61. Fernandez-Recio J, Totrov M, Abagyan R. Identification of protein-protein interaction sites from docking energy landscapes. J Mol Biol. 2004; 335:843–65. [PubMed: 14687579]

- 62. De Vries SJ, van Dijk M, Bonvin AMJJ. The HADDOCK web server for data-driven biomolecular docking. Nat Protoc. 2010; 5:883–97. [PubMed: 20431534]
- 63. Vangone, A.; Bonvin, AMJJ. SBGRid Data Bank, V1. 2015. HADDOCK decoys for 55 new entries in Docking Benchmark 5.
- 64. Moal IH, Jiménez-García B, Fernandez-Recio J. CCharPPI web server: computational characterization of protein-protein interactions from structure. Bioinformatics. 2015; 31:123–5. [PubMed: 25183488]
- 65. Visscher KM, Kastritis PL, Bonvin AMJJ. Non-interacting surface solvation and dynamics in protein-protein interactions. Proteins. 2015; 83:445–58. [PubMed: 25524313]
- 66. Shen M-Y, Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 2006; 15:2507–24. [PubMed: 17075131]
- 67. Pons C, Talavera D, la Cruz de X, Orozco M, Fernandez-Recio J. Scoring by intermolecular pairwise propensities of exposed residues (SIPPER): a new efficient potential for protein-protein docking. J Chem Inf Model. 2011; 51:370–7. [PubMed: 21214199]
- 68. Pierce B, Weng Z. A combination of rescoring and refinement significantly improves protein docking performance. Proteins. 2008; 72:270–9. [PubMed: 18214977]
- Andrusier N, Nussinov R, Wolfson HJ. FireDock: fast interaction refinement in molecular docking. Proteins. 2007; 69:139–59. [PubMed: 17598144]
- 70. Moal IH, Dapk nas J, Fernandez-Recio J. Inferring the microscopic surface energy of protein-protein interfaces from mutation data. Proteins. 2015; 83:640–50. [PubMed: 25586563]




Figure 1.

(A) Performance of four docking algorithms on the new cases in the benchmarks, showing whether acceptable/medium/high quality structures evaluated using the CAPRI criteria were present in the top 1/5/10/50/100 predictions for each case (denoted by T1, T5, T10, T50, and T100, respectively). Also shown are the overall success rates (bottom), complex type (left) and binding energy where available (far left). The complexes are ordered first by the difficulty category, then by I-RMSD. (B) Evaluation of affinity prediction methods. Complexes are ordered by increasing experimental affinities, to which the predicted affinities were fitted using linear regression in order to compare the performance of various prediction methods. The performances are grouped using a weighted average linkage agglomerative clustering algorithm (bottom). Correlations against the experimental data are shown at the top, for all the new benchmark cases as well as for the flexible complexes (I-RMSD 1.0 Å) only or for the rigid complexes (I-RMSD < 1.0Å) only. Also shown are the I-RMSD values (right), complex type (left), and the docking success rate at top 10 predictions (far left).




Figure 2. Interface area vs. experimental binding energy of the benchmark cases with successful docking runs (green; at least three docking protocols yielding acceptable predictions in the top 100) or unsuccessful docking runs (red; at most one docking protocol yielding acceptable predictions in the top 100).




Figure 3.

Crystal structure (2GAF) of the complex of Poly(A) polymerase (orange) VP55 and Vaccinia protein VP39 (blue and cyan). Vaccinia protein VP39 residues that are within the Poly(A) polymerase cavity are colored blue, while the residues outside the cavity are colored cyan.

Table 1

New cases in the docking benchmark 5 and affinity benchmark 2.

Mayor A YXVL HL Munic reference anthody 125.2H Fab 1108.A/G Inneclutie 18 1.33 2.3 2XYL HLL A 2WOL JH Kindramel Fab fragment 1018.A/G Inneclutie 18 1.33		Cat.a	Cat. ^a PDB ID 1 ^b	Protein 1	PDB ID 2 ^b	Protein 2	I.RMSD (Å)	$_{(\mathring{A}^2)}^{\mathrm{ASA}^{\mathcal{C}}}$	Kd (M)	Gd (kcal/mol)	(°C)
A 2VXU,HL Munine reference anathody 12-2H Fab 1081.A6 Interleukin-18 1.33 A 3EWD,HL KXM I8 Fab fragment 10M1.A Prior protein fragment 1.13 A 3EWD,LH Insignand Fab fragment 19M1.A Interleukin-12 domain 1.13 A 3EWD,LH Insignand Fab fragment 1F4.AB Interleukin-12 domain 1.13 A 3RWY,LH Ami-Shi SH Gimene Fab fragment 1F6.AB Interleukin-12 domain 0.30 A 4RW,LH CVICASE Fab Ami-Shi SH Gimene Fab fragment 1F0.AB December Active	Rigid body										
A 3MD_AHL CSM 18 Fab fragment 10MLA First protein fragment 1.13 A 3HOALH Effiltzmanb Fab fragment 3F74_A Inception alphe-L1 domain 0.39 A 3HAM_LH Userkinamba Fab fragment 1F45_AB Inceptable-L1 domain 0.93 A 3HAM_LH Userkinamba Fab fragment 1F45_AB Inceptable-L1 domain 0.93 A 3MAY_LH Actif-Bb Grine Hedgeng Neventinal domain 0.50 A 4MA_L GUTSA Soviet Hedgeng Neventinal domain 0.50 A 4F6H_H CNTORSS Fab DNA MRT-A MRT-A 0.05 1.05 A 4GN_LH CAVEAHL CAVEAHL GAVITA 1.00_LA MRT-Influenza virus hemagalutinin 0.50 A 4GN_H GAVEAHL GAVEAHL GAVITA 1.00_LA <	2VXT_HL:I	٧	2VXU_HL	Murine reference antibody 125-2H Fab	1J0S_A(6)	Interleukin-18	1.33	2163	5.33e-10	-12.65	
A SEOP_LH Effiltzomab Fab fragment 3F7.4.A Inegran alpha-L1 domain 29 A SHAW_LH Usakhimab Fab fragment 1145.AB Inerclusian-12 0.73 A SHAW_LH Aun-Shh SEI chimeur Fab fragment 1145.AB Inerclusian-12 0.73 A SHAY_LH Aun-Shh SEI chimeur Fab fragment 1100.A Mort Holgebop N-terminal domain 0.43 A 4704_LH CRO14 Fab CRO14 Fab 100.A Mort Holgebop N-terminal domain 0.81 A 4704_LH CRO14 Fab CRO14 Fab 100.A MCP-1 100.A 1.81 A 4704_LH CRO14 Fab CRO14 Fab 1100.A MCP-1 100.A 1.81 A 4704_LH Crockizumab antibody fragment 411B.A Inerclusia-1 bear 0.61 1.81 A 4704_HL Crockizumab antibody fragment 411B.A Inerclusia-1 bear 0.61 1.81 A 4704_HL Crockizumab antibody fragment 411B.A Inerclusiachine branching 0.61 1.81 B 3010_A Blatzola Blatzola 111B.A Inerclusiaching protein VF39 <	2W9E_HL:A	4	2W9D_HL	ICSM 18 Fab fragment	1QM1_A	Prion protein fragment	1.13	1677	1.3e-10	-13.49	
A AHMVLH Ustekinnmab Fab IF45.AB Interleukir-12 0.33 A AMXVLH Anti-Shh SEI chimera Fab fingment 3MINA Sonie Hedgelog N-terminal domain 0.48 A 4 SWY_LH Arricabb Erleib ACPL DER P1 allergem 0.49 A 4 SWY_LH CNTO888 Fab DIOU_A MCP-1 0.50 A 4 GYZ_HL CRANDARD ACPL 100_LA MCP-1 A 4 GYZ_HL Crankizuman antibody fragment 11B_A Increasivir- bera 0.61 A 4 GXZ_HL Gevokizuman antibody fragment 11B_A Increasivir- bera 0.61 A 4 GXY_HL IF antibody 11B_A Increasivir- bera 0.61 A 4 GXY_HL IF antibody 11B_A Increasivir- bera 0.61 B 3 GYO_A BLABYOT Carriants BPHAAD 10FG_A 0.70 0.61 B 2 YYY_A Book/A) polymerase VPS3 10FG_A 0.70 0.70 B 2 YYY_A Reveroing representable brand	3EOA_LH:I	A	3Е09_LН	Efalizumab Fab fragment	3F74_A	Integrin alpha-L I domain	0.39	1272	2.2e-9	-11.81	25
A MXV_LH Anni-Shh SEI chimera Fab fragment 3HVLA Sonic Hedgebtog Nerminal domain 0.48 A MXV_LD CIFeb CHERD ABTOL CHERD CHERD DEPL allegen 0.50 A MYL_CD CHTGB CALTER CHERD MCP-1 DEPL DESCRIPTION 0.50 A 45QH_HL CROURDSR Fab DEDL_A MCP-1 MIDLAGE DESCRIPTION 0.50 A 45QH_HL CRONIDAGE CROSIZAMIA CHERD HIB_A INTERCLABIAN IN THE ALL AND	3HMX_LH:AB	Ą	знмw_сн	Ustekinumab Fab	1F45_AB	Interleukin-12	0.73	1841			
A 3FV_LCD 4CIFab CMCP ABCP_LAM CMCPABCDER ARPT_LAM CMCPABCDER ARPT_LAM CMCPABCDER ARPT_LAM CMCPABCDER ARPT_LAM A	3MXW_LH:A	∢	3MXV_LH	Anti-Shh 5E1 chimera Fab fragment	3M1N_A	Sonic Hedgehog N-terminal domain	0.48	1696	7e-9	-11.31	30
A HDN3_LH CNTO888 Fabr IDDI_A MCP-1 IDDI_A MCP-1 IDDI_A MCP-1 IDDI_A MCP-1 IDDI_A MCP-1 IDDI_A MCP-1 IDDI_A IDDI	3RVW_CD:A	A	3RVT_CD	4C1Fab	3F5VA	DER P 1 allergen	0.50	1383	1.9e-8	-10.53	25
A 4PQH_HLL CR9114 Fab CFR0_ABCDEF FAN1 influenza virus hemaggutinin 108 A 4GSZ_HL canakinumab antibody fragment 41B_A Inter-teakin-1 beta 0.49 A 4GSZ_HL cevokizumab antibody fragment 41B_A Inter-teakin-1 beta 0.49 A 4GX_HL gevokizumab antibody fragment 1BT_A 1RT_A 1RT-teachin-1 beta 0.49 B 4GX_HL plantody fragment 1BT_A 1RT_A 1RT-teachin-1 beta 0.49 B 4GX_HL plantody fragment 1BT_A 1RT-A 1RT-beta-bactamase 0.49 B 3UULA blantody fragment 1BT_A 1APA_A 1APA 1APA 1APA 0.45 1APA 1APA 0.45 1APA 0.45 1APA 0.45 1APA 0.45 1APA 0.45 1APA 0.45 1APA 0.46 1APA 0.46 1APA 0.46 1APA 0.46 1APA 0.46 1APA 0.46 1APA 0.44 0.44 0.4	4DN4_LH:M	A	4DN3_LH	CNTO888 Fab	1DOL_A	MCP-1	0.81	1317	3.8e-11	-14.22	25
A 4GSZ-HL canakinamab antibody fragment 41B.A Interleukin-1 beta 61 A 4GKZ-HL Gevokizumab antibody fragment 41B.A Interleukin-1 beta 0.49 A 4GKZ-HL Gevokizumab antibody fragment 11B.A 1918 HI Hemagglutinin 0.49 E 4GKZ-HL Fla antibody fragment 18T.Z-HIKLA 1918 HI Hemagglutinin 0.49 E 3GO-A BLP-II 18T.Z-HIKLA 1918 HI Hemagglutinin 0.44 E 3GO-A BLP-II 18T.Z-HIKLA 17E-I-I abuta-bactamase 0.44 E 3GO-A Poly(A) polymerase VP55 1VT-A Vaccinia protein VP39 0.69 E 2VYE-A Ferredoxin reductase BPHA4 2E4P.A 18phenyl dioxygenase ferredoxin submit 0.69 E 1ASS-A SUMO-conjugating enzyme UBC9 3A4R.A NFATCZ-interaction protein NP39 0.69 E 1ASS-A DNA polymerase beta 3T.A.A Reduced XRCCI.N-terminal domain 0.69 E 1AVA.A DNA repair protein XRCCI by SorPla 3T.A.A	4FQI_HL:ABEFCD	Ą	4FQH_HL	CR9114 Fab	2FK0_ABCDEF	H5N1 influenza virus hemagglutinin	1.08	1459	9e-10	-12.55	30
A 4G6K_HL Gevokizumab antibody fragment 4IIB_A Interleukin-1 beta 10.49 A 4GXV_HL IF1 antibody IRILA 1918 HI Hemagglutinin 0.78 E 4GXV_HL IF1 antibody IRILA 1918 HI Hemagglutinin 0.78 E 3GIO_A BLIP-II 1871_A 178A-1 beta-lactamase 0.44 E 3GIU_A Eakayotic translation initiation factor 2-alpha kinase 2 1946_A 178A-1 beta-lactamase 0.44 E 3WIU_A Poly(A) polymerase VP55 147A-A 128A-A 147A-A	4G6J_HL:A	Ą	4G5Z_HL	Canakinumab antibody fragment	4I1B_A	Interleukin-1 beta	0.61	1893	4.1e-9	-11.44	25
A 4 GXV_HL IFT antibody IRUZ_HIIGIM IPLH Hemaggutinin 0.78 E1 3(0,A+) BLIP-II 18TL_A TEM-I beta-lactamase 0.44 E2 3(0,A+) BLIP-II 18TL_A TEM-I beta-lactamase 0.44 E8 3(0,A-) Bukayotic translation initiation factor 2-alpha kinase 2 1046_A 1046_A 1.25 E8 3(0,A-) Poly(A) polymerase VPS5 100 1.24 1.55 E9 1 ASS_A SUMO-conjugating enzyme UBC9 2E4_A NAT/C2-interacting protein SLD2 ubiquitin-like domain 0.50 E1 1 ASS_A SUMO-conjugating enzyme UBC9 3AR_A NAT/C2-interacting protein SLD2 ubiquitin-like domain 0.72 E1 3 YM_AB DNA repair protein RC1 3K7_AB NAT/C2-interacting protein SLD2 ubiquitin-like domain 0.72 E1 3 YM_AB DNA repair protein RC1 3VLA_AB NA ligase III-alpha BRC7 domain 0.72 E1 4 HWX_AB Nouverly protein SCNPI 107_AB NA ligase III-alpha subunit domain 0.72 E2 1 GQ_A <td< td=""><td>4G6M_HL:A</td><td>Ą</td><td>4G6K_HL</td><td>Gevokizumab antibody fragment</td><td>4I1B_A</td><td>Interleukin-1 beta</td><td>0.49</td><td>1673</td><td>2.9e-10</td><td>-13.01</td><td>25</td></td<>	4G6M_HL:A	Ą	4G6K_HL	Gevokizumab antibody fragment	4I1B_A	Interleukin-1 beta	0.49	1673	2.9e-10	-13.01	25
E1 3Q0_A BLIPII 1BTL_A TEM-I beta-lactamase 0.44 E2 3UU_A Enkayotic translation initiation factor 2-alpha kinase 2 1Q46_A 1CFA-1 alpha subunit 1.35 E2 3UU_A Poly(A) polymerase VP55 1VPT_A Vaccinia protein VP39 0.69 E2 3WG_A Poly(A) polymerase VP55 1VPT_A Naccinia protein VP39 0.69 E3 1 A3S_A SUMO-conjugating enzyme UBC9 3AR_A NAFACZ:interacting protein SLD2 ubjquitin-like domain 0.69 E4 1 A3S_A DNA polymerase beta 3K7_A Reduced XRCCI.N-terminal domain 0.61 E4 3 LVM_AB Cysteine desulfurase lecS 1DCL_A(12) Sulfurtransferase tusA 0.64 E4 3 VM_AB DNA repair protein XRCCI 3VP_AB Naviagucan-specific endo-beta-1,4-glucanase A 0.51 E4 4 HWX_AB Neutral protein set inhibitor ScNPI 1UT_A Alpha actin 0.64 E5 1 GQ_A 1 Ota toxin component IA 1UT_A Alpha actin 0.64 C 1 Ota CA Alpha-1	4GXU_MN:ABEFCD	⋖	4GXV_HL	1F1 antibody	1RUZ_HIJKLM	1918 HI Hemagglutinin	0.78	1830	6.2e-9	-11.2	
EX 3 UIU_A bukayotic translation initiation factor 2-alpha kinase 2 1Q4_A derez alpha subunit 1.35 ER 3 OWG_A boly(A) polymerase VP55 1 VPT_A Vaccinia protein VP39 0.69 ER 2 VYE_A Ferredoxin reductase BPHA4 2E4P_A Biphenyl dioxygenase ferredoxin subunit 0.69 ER 1 A3S_A SUMO-conjugating enzyme UBC9 3A4R_A NFATC2-interacting protein SLD2 ubquirin-like domain 0.72 ER 1 LXM_AB Cysteine desulfurase beta 3K77_A Reduced XRCC1, N-terminal domain 0.64 ER 3 LVM_AB Cysteine desulfurase beta 1DCJ_A(12) Sulfurtransferase usA 0.64 ER 3 LVM_AB DNA repair protein XRCC1 3VL3_A Xyloglucan-specific endo-beta-1-4-glucanase A 0.51 EI 4 HWX_AB Neutral protein as inhibitor ScNPI 1UJ_A Alpha actin 0.64 0.64 ESGFH OX LQ_ABCD AlWACABC W.V.LACABC Neutral protein sub unit 0.74 0.74 Alpha actin 0.64 0.61 ESGFH OX 1 VRQ_ABCD	1JTD_B:A	EI	3QI0_A	BLIP-II	1BTL_A	TEM-1 beta-lactamase	0.44	2180	2.72e-11	-14.41	25
ER 30WG-A Poly(A) polymerase VP55 IVPT_A Vaccinia protein VP39 0.69 ER 2YYE_A Ferredoxin reductase BPHA4 2E4P_A Biphenyl dioxygenase ferredoxin subunit 0.60 ER 1A3S_A SUMO-conjugating enzyme UBC9 3A4R_A NFATC2-interacting protein SLD2 ubiquitin-like domain 0.61 ER 3LVM_AB DNA polymerase beta 3K77_A Reduced XRCC1, N-terminal domain 0.64 ER 3LVM_AB ONA repair protein SRC1 3PC7_A Nelforcase tusA 0.61 ER 3VLA_A DNA repair protein SRC1 3VL8_A Xyloglucan-specific endo-beta-1,4-glucanase A 0.51 EI 4HWX_AB Neutral protein se inhibitor ScNPI 1CTK_A Zinc endoprotease 0.51 EI 4HWX_AB Neutral protein beta subunit 1UJ_A Apha actin 0.64 0.61 SSG 1GQ-A 1GRQ_ABCD KV beta2 protein beta subunit Guanine nucleotide-binding protein G(I) 1WJ_AB RVI.2 potassium channel N-terminal domain 0.62 CG 1GFL_AB Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2W	2A1A_B:A	ES	3UIU_A	Eukayotic translation initiation factor 2-alpha kinase 2	1Q46_A	eIF2 alpha subunit	1.35	1186			
ER 24VF_A Ferredoxin reductase BPHA4 2E4_A Biphenyl dioxygenase ferredoxin subunit 0.60 ER 1A3S_A SUMO-conjugating enzyme UBC9 3A4R_A NFATC2-interacting protein SLD2 ubiquitin-like domain 0.72 ER 1BPB_A DNA polymerase beta 3K77_A Reduced XRCC1, N-terminal domain 0.64 ER 3LVM_AB Cysteine desulfurase IscS 1DCJ_A(12) Sulfurtransferase tusA 0.61 ER 3LVM_AB DNA repair protein XRC1 3PC_A DNA ligase III-alpha BRCT domain 0.50 EI 4HWX_AB Neutral protein ase inhibitor ScNPI 1CTK_A Xiyoglucan-specific endo-beta-1,4-glucanase A 0.51 ES 1GIQ_A Iota toxin component IA 1UJ_A Alpha actin 0.62 SIGCA KV beta2 protein beta subunit 1QDV_ABCD KV 1.2 potassium channel N-terminal domain 0.63 CH 1D4T_AB Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV_A Fyn kinase SH3 domain 0.63 OR 1GFL_A Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2WB_A RGS1 100 Traini	2GAF_D:A	ER	30WG_A	Poly(A) polymerase VP55	1VPT_A	Vaccinia protein VP39	69.0	3368	1.2e-9	-12.17	
EI 1A35_A SUMO-conjugating enzyme UBC9 3A4R_A NFATC2-interacting protein SLD2 ubiquitin-like domain 0.72 ER 1BPB_A DNA polymerase beta 3K77_A Reduced XRCCI, N-terminal domain 0.54 ER 3LVM_AB Cysteine desulfurase IscS 1DCJ_A(12) Sulfurtransferase tusA 0.81 ER 3FCG_A DNA repair protein XRCCI 3FC_A DNA ligase III-alpha BRCT domain 0.50 EI 4HWX_AB BDGP SAPCA Xyloglucan-specific endo-beta-1,4-glucanase A 0.51 EI 4HWX_AB Neutral proteinase inhibitor ScNPI 1GTK_A Zinc endoprotease 0.51 EGFH OX 1GQ_A Iota toxin component IA 1III_A Alpha actin Alpha actin 0.68 CSGFH OX 1GR_ABCD KV beta2 protein beta subunit 1QDV_ABCD KV 1.2 potassium channel N-terminal domain 0.62 CSGFH OX 1GF_AB Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV_LAB RGSI 1CA 1.2 CSG_A(R) 1GF_AB Alpha-1 subunit Guanine nucleotide-binding	2YVJ_A:B	ER	2YVF_A	Ferredoxin reductase BPHA4	2E4P_A	Biphenyl dioxygenase ferredoxin subunit	09.0	1377			
ER IBPB_A DNA polymerase beta 3K77_A Reduced XRCC1, N-terminal domain 0.64 ER 3LVM_AB Cysteine desulfurase IscS 1DCJ_A(12) Sulfurtransferase tusA 0.81 ER 3PCG_AB DNA repair protein XRCC1 3PCT_AB DNA ligase III-alpha BRCT domain 0.50 EI 4HWX_AB BOGP 3VLS_AB Xjoglucan-specific endo-beta-1,4-glucanase A 0.51 EI 4HWX_AB Neutral proteinase inhibitor ScNPl 1UT_A Alpha actin 0.50 SEGFH 0X 1GIQ_A kV beta2 protein beta subunit 1UJ_A Alpha actin 0.62 CEGFH 0X 1QRQ_ABCD KV beta2 protein beta subunit 1QDV_ABCD KV1.2 potassium channel N-terminal domain 0.62 CEGFH 0X 1QRQ_ABCD Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGSI 1CRC potassium channel N-terminal domain 0.50 CEGFH 0X 1GFL_AB Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGSI 0.51 0.54 CH 1SG_AGS 1SG_AGS<	3A4S_A:D	EI	1A3S_A	SUMO-conjugating enzyme UBC9	3A4R_A	NFATC2-interacting protein SLD2 ubiquitin-like domain	0.72	1116	2.81e-6	7.57	25
ER 3LVM_AB Cysteine desulfurase IscS IDCJ_A(12) Sulfurtransferase tusA 0.81 ER 3PCG_A DNA repair protein XRCC1 3PC_A DNA ligase III-alpha BRCT domain 0.50 EI 3VLA_A EDGP 3VLB_A Xyloglucan-specific endo-beta-1,4-glucanase A 0.51 EI 4HWX_AB Neutral proteinase inhibitor ScNPI 1IJ_A Alpha actin 0.00 ES 1GIQ_A tota toxin component IA 1IJ_A Alpha actin 0.68 S:EGFH 0X 1QR_ABCD KV beta2 protein beta subunit 1QDV_ABCD KV1.2 potassium channel N-terminal domain 0.68 C:GFFH 0X 1DT_AB SAP-SLAM Complex 3UA6_A Fyn kinase SH3 domain 0.52 OG 1GFL_AB Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGS1 RGS1 OG 1GFL_AB TolA C-terminal domain 2X9B_A G3P TolA binding domain 0.54	3K75_D:B	ER	1BPB_A	DNA polymerase beta	3K77_A	Reduced XRCC1, N-terminal domain	0.64	1195	1.1e-7	-9.49	
ER 3PCG-A DNA repair protein XRCC1 3PC7-A DNA ligase III-alpha BRCT domain 0.50 EI 3VLA_A EDGP control of a control of component I A component I A control of a control of component I A control of a contro	3LVK_AC:B	ER	3LVM_AB	Cysteine desulfurase IscS	1DCJ_A(12)	Sulfurtransferase tusA	0.81	1609	3.04e-7	-8.89	25
EI 3VLA_A EDGP 3VL8_A Xyloglucan-specific endo-beta-1,4-glucanase A 0.51 EI 4HWX_AB Neutral proteinase inhibitor ScNPI 1C7K_A Zinc endoprotease 0.90 S:EGFH 0X 1GIQ_A Iota toxin component IA 1IJI_A Alpha actin 0.68 S:EGFH 0X 1QR_ABCD KV beta2 protein beta subunit 1QDV_ABCD KV1.2 potassium channel N-terminal domain 0.62 OX 1D4T_AB SAP-SLAM Complex 3UA6_A Fyn kinase SH3 domain 0.52 OG 1GFL_A Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGS1 0.54 OR 1GFL_AS TolA C-terminal domain 2X9B_A G3P TolA binding domain 0.54	3PC8_A:C	ER	3PC6_A	DNA repair protein XRCC1	3PC7_A	DNA ligase III-alpha BRCT domain	0.50	1240	1.02e-7	-9.54	
El HWX_AB Neutral proteinase inhibitor ScNPI IUJ_A Alpha actin diversement IA Dia toxin component II Dia toxin component IA Dia toxin component IA Dia toxin component II Dia toxin component IA Dia toxin component II Dia toxin com	3VLB_A:B	EI	3VLA_A	EDGP	3VL8_A	Xyloglucan-specific endo-beta-1,4-glucanase A	0.51	2020			
ES IGIQ_A lota toxin component IA IIII_A Alpha actin 0.68 DC:EGFH OX IQRQ_ABCD KV beta2 protein beta subunit IQDV_ABCD KV1.2 potassium channel N-terminal domain 0.62 C OX ID4T_AB SAP-SLAM Complex 3UA6_A Fyn kinase SH3 domain 1.22 OG IGFI_A Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BVI_A RGSI 0.54 OR IS62_A(8) TolA C-terminal domain 2X9B_A G3P TolA binding domain 1.33	4HX3_BD:A	EI	4HWX_AB	Neutral proteinase inhibitor ScNPI	1C7K_A	Zinc endoprotease	06.0	2086	9-99	-7.41	37
DC:EGFH OX 1QRQ_ABCD KV beta2 protein beta subunit 1QDV_ABCD KV1.2 potassium channel N-terminal domain 0.62 CX 1D4T_AB SAP-SLAM Complex 3UA6_A Fyn kinase SH3 domain 1.22 OG 1GFI_A Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGS1 OG 1GFLA 7 TolA C-terminal domain 2X9B_A G3P TolA binding domain 1.33	4H03_A:B	ES	1GIQ_A	Iota toxin component IA	1IIJ_A	Alpha actin	89.0	1474			
OX 1D4T_AB SAP-SLAM Complex 3UA6_A Fyn kinase SH3 domain 1.22 OG 1GFL_A Alpha-1 subunit Guanine nucleotide-binding protein G(1) 2BV1_A RGS1 OR 1S62_A(8) TolA C-terminal domain 2X9B_A G3P TolA binding domain 1.33	1EXB_ABDC:EGFH	XO	1QRQ_ABCD	KV beta2 protein beta subunit	1QDV_ABCD	KV1.2 potassium channel N-terminal domain	0.62	3558			
OG 1GFI_A Alpha-1 subunit Guanine nucleotide-binding protein G(I) 2BV1_A RGS1 0.54 OR 1S62_A(8) TolA C-terminal domain 2X9B_A G3P TolA binding domain 1.33	1M27_AB:C	XO	$1D4T_AB$	SAP-SLAM Complex	3UA6_A	Fyn kinase SH3 domain	1.22	799	3.45e-6	-7.45	25
OR 1S62_A(8) TolA C-terminal domain 2X9B_A G3P TolA binding domain 1.33	2GTP_A:D	90	1GFI_A	Alpha-1 subunit Guanine nucleotide-binding protein G(I)	2BV1_A	RGS1	0.54	1442			
	2X9A_D:C	OR	1S62_A(8)	TolA C-terminal domain	2X9B_A	G3P ToIA binding domain	1.33	1571	4.4e-6	-7.31	25

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	Cat.a	PDB ID 1 ^b	Protein 1	PDB ID 2b	Protein 2	I-RMSD (Å)	$_{(\mathring{\mathbf{A}}^2)}^{\mathbf{ASA}^c}$	Kd (M)	Gd (kcal/mol)	T (°C)
3BIW_A:E	XO	3BIX_A	Neuroligin-1	2R1D_A	Neuroligin-1-beta	0.39	1191	9.7e-8	-9.41	20
3H2V_A:E	XO	3MYI_A	Vinculin tail domain	1WI6_A(8)	Raverl RRM1 domain	0.80	1263	2.21e-5	-6.31	23
3P57_AB:P	XO	3KOV_AB	MEF2A	3102_A	p300 TAZ2 domain	0.53	1291			
3P57_CD:P	XO	3KOV_AB	MEF2A	3102_A	p300 TAZ2 domain	0.74	1177			
3P57_IJ:P	XO	3KOV_AB	MEF2A	3102_A	p300 TAZ2 domain	0.91	1126			
4M76_A:B	OR	1C3D_A	C3D	1M1U_A	Integrin alpha-M CD11B A-domain	0.43	1046	4.5e-7	-8.66	25
Medium										
3E01_AB:CF	Ą	3E00_AB	GC-1008 Fab fragment	1TGJ_AB	Transforming Growth Factor-Beta 3	1.37	1630			
3G6D_LH:A	A	3G6A_LH	CNTO607 Fab	1IK0_A(10)	Interleukin-13	1.86	1793	1.84e-11	-14.65	25
3HI6_XY:B	Ą	3HI5_HL	AL-57 Fab fragment	1MJN_A	Integrin alpha-L I domain	1.65	1871	4.7e-6	-7.27	
3L5W_LH:I	Ą	згле_сн	C836 Fab	1IK0_A(11)	Interleukin-13	0.48	1138	5.4e-11	-14.01	25
3V6Z_AB:F	А	3V6F_AB	FabE6	3KXS_F	Capsid protein assembly domain	1.83	1922	3.3e-9	-11.57	
4FZA_A:B	ER	1UPL_A	MO25 alpha	3GGF_A	Serine/threonine-protein kinase MST4	2.04	1695			
4IZ7_A:B	EI	1ERK_A	Non-phosphorylated ERK	2LS7_A(1)	PEA-15 Death Effector Domain	1.56	1202	1.33e-7	-9.44	27
4LW4_AB:C	ES	4LW2_AB	Cysteine desulfurase CsdA	1NI7_A(8)	Cysteine desulfuration protein CsdE	1.60	1610			
3AAA_AB:C	OX	3AA7_AB	Actin capping protein	1MYO_A(30)	Myotrophin	1.78	1686	2.1e-8	-10.3	20
3AAD_A:D	XO	1EQF_A	Double bromodomain	1TEY_A(13)	Histone chaperone ASF1	2.00	1461			
3BX7_A:C	OX	3BX8_A	Lipocalin 2	30SK_A	CTLA-4 extracellular domain	1.63	2349	9e-9	-10.98	25
3DAW_A:B	OX	1IJJ-A	Alpha actin	2HD7_A(5)	Twinfilin-1 C-terminal domain	1.49	2323	2e-5	-6.41	
3R9A_AC:B	OR	1H0C_AB	Alanine-glyoxylate aminotransferase	2C0M_A	PEX5P TPR repeat domain	1.91	1926	3.5e-6	-7.44	25
3SZK_DE:F	XO	3ODQ_AB	MetHaemoglobin	2H3K_A	ISDH-N1	2.10	1263	9.01e-8	-9.45	20
3S9D_B:A	OR	1N6U_A(15)	IFNAR2	1ITF_A(9)	IFNa2	1.69	1841	3e-9	-11.63	
4JCV_ADBC:E	XO	1VDD_ABCD	Recombinational repair protein RecR	1W3S_A	DNA repair protein RecO	1.62	1949			
Difficult										
3FN1_B:A	ER	2EDI_A(5)	UQ_con domain from NEDD8-conjugating enzyme UBE2F	2LQ7_A	NEDD8-activaating enzyme E1 catalytic subunit	3.65	1897			
3H11_BC:A	ER	$4JJ_AB$	Caspase-8	3H13_A	c-FLIPL protease-like domain	3.79	3169			
4GAM_AFBGCH:D	ER	1XVB_ABCDEF	Methane monooxygenase hydroxylase	1CKV_A(9)	Methane monooxygenase regulatory protein B	5.79	6671			
1RKE_A:B	OX	1SYQ_A	Vinculin head	3MYI_A	Vinculin tail	4.25	2614			
3AAD_A:B	XO	1EQF_A	Double bromodomain	1TEY_A(4)	Histone chaperone ASF1	4.37	1654			
3F1P_A:B	XO	1P97_A(9)	HIF2 alpha C-terminal PAS domain	1X00_A(5)	ARNT C-terminal PAS domain	2.52	1919	1.4e-6	-7.85	20

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

	Cat.a	PDB ID 1 b	Protein 1	PDB ID 2^b	Protein 2	I-RMSD (Å)	$_{(\mathring{\mathbf{A}}^2)}^{\mathrm{ASA}^{\boldsymbol{c}}}$	Kd (M)	Gd (kcal/mol)	T (°C)
L89_ABC:M	OR	3L88_ABC	Ad21 fiber knob	1CKL_A	CD46 SCR1 and SCR2 domains	2.51	2167	2.84e-7 -8.93	-8.93	25

^aCategories: antibody-antigen (A); enzyme-inhibitor (EI); enzyme-substrate (ES); enzyme complex with a regulatory or accessory chain (ER); others, G-protein containing (OG); others, receptor containing (OR); others, miscellaneous (OX).

 b Numbers in parentheses denote the NMR model that was chosen as the unbound structure.

^cChange in solvent accessible surface area upon complex formation, calculated using the NACCESS program (see methods).

 d Calculated using $G = RT \ln Kd$, where R is the gas constant and T the absolute temperature, with T set to 298.15 K when unknown.

Table 2

Composition of the updated docking and affinity benchmarks (in parentheses are values for the previous versions of the benchmarks, docking v4 and affinity v1).

	Do	cking	Af	finity
	N	%	N	%
All	230 (175)		179 (144)	
Enzyme containing	88 (71)	38% (41%)	69 (61)	39% (42%)
Antibody-antigen	40 (24)	17% (14%)	33(19)	18% (13%)
Others	102 (80)	45% (45%)	77 (64)	43% (45%)
Rigid-body ^a	151(119)	65% (68%)		_
$Medium^a$	45 (29)	20% (17%)		
$\mathrm{Difficult}^a$	34 (27)	15% (15%)		
Rigid (I-RMSD<1.0Å) ^a			93(75)	52% (52%)
Flexible (I-RMSD>1.0Å) ^a			86 (69)	48% (48%)

 $^{^{}a}$ See Methods for definition